Results 41 to 50 of about 117 (67)
The SChISM study: Circulating cell-free DNA size profiles as predictors of progression in advanced carcinoma treated with immune-checkpoint inhibitors
BackgroundCirculating cell-free DNA (cfDNA) offers a promising noninvasive way to predict resistance to immune-checkpoint inhibitors (ICI), for which robust biomarkers are still lacking.MethodsThe SChISM (Size CfDNA Immunotherapy Signature Monitoring ...Boutonnet, Audrey, Fina, Frederic, Della-Negra, Lucie, Nguyen Phuong, Linh, Tomasini, Pascale, Greillier, Laurent, Zakrasjek, Romain, Garcia, Jean-Charles, Salas, Sébastien, Ginot, Frédéric, Deville, Jean-Laurent, Benzekry, Sébastien +11 morecore +4 more sourcesIntegrating tumor kinetics and circulating cell-free DNA markers through mechanistic modeling for early prediction of immunotherapy response
International audienceMany cancer patients undergoing immune-checkpoint inhibition (ICI) experience early progression(EP), defined as progression at the first imaging evaluation.Fina, Frederic, Nguyen Phuong, Linh, Greillier, Laurent, Gaudy-Marqueste, Caroline, Garcia, Jean-Charles, Salas, Sébastien, Deville, Jean-Laurent, Benzekry, Sébastien +7 morecore +1 more sourceCirculating cell-free DNA size distribution as a prediction marker for early progression undergoing immune checkpoint inhibitors
International audienceIntroduction: Despite a significant proportion (20 to 40%)[1] of advanced cancer patients having long-term response to treatment with immune checkpoint inhibitors (ICI), many of them do not respond at all and experience early ...Boutonnet, Audrey, Fina, Frederic, Nguyen Phuong, Linh, Greillier, Laurent, Gaudy-Marqueste, Caroline, Salas, Sébastien, Ginot, Frédéric, Deville, Jean-Laurent, Benzekry, Sébastien +8 morecore +2 more sourcesSizing and concentration analysis of cfDNA using Biabooster technology: Results from a prospective plasma‐based collection of 77 patients with locally advanced unresectable esophageal cancer
International audienceAbstract Locally advanced esophageal carcinoma remains of poor prognosis correlated with tumor stage. Albeit liquid biopsy approach offers promising results to monitor high‐risk patients in various solid tumors, the lack of specific Le Sourd, Samuel, Jouve, Ariane Darut, Gibert, Sophie, Taillez, Alexandre, Modesto, Anouchka, Vendrely, Véronique, Seva, Catherine, Delmas, Caroline, Ronchin, Philippe, Leignel, Delphine Argo, Guimbaud, Rosine, Moyal, Elizabeth, Riou, Olivier, Delord, Jean Pierre, Cordelier, Pierre, Pezzella, Veronica, Paumier, Amaury, Martin-Babau, Jérôme, Tougeron, David, Leroy, Thomas, Quéro, Laurent, Hanoun, Naima +21 morecore +1 more sourceMechanistic Modeling of cfDNA Fragmentome Dynamics Predicts Progression to Immunotherapy
BackgroundPlasma cell-free DNA (cfDNA) shows promise as predictive cancer biomarker, but mechanisms governing cfDNA production/fragmentation/elimination dynamics, and their relationships with tumor burden and disease progression, remain poorly understood.Boutonnet, Audrey, Salas, Sebastien, Nguyen Phuong, Linh, Tomasini, Pascale, Greillier, Laurent, Garcia, Jean-Charles, Ginot, Frédéric, Deville, Jean-Laurent, Fina, Frédéric, Benzekry, Sébastien +9 morecore +3 more sourcesCell-Free DNA Fragmentome Dynamics as a Biomarker for Immune-Checkpoint Inhibition in Advanced Carcinoma
International audienceEarly prediction of resistance to immunotherapy is a major challenge in oncology. The ongoing SChISM (Size Cell-fre DNA (cfDNA) Immunotherapies Signature Monitoring) clinical study proposes an innovative approach based on patented ...Boutonnet, Audrey, Fina, Frederic, Della-Negra, Lucie, Nguyen Phuong, Linh, Tomasini, Pascale, Greillier, Laurent, Garcia, Jean-Charles, Salas, Sébastien, Ginot, Frédéric, Zakrajsek, Romain, Deville, Jean-Laurent, Benzekry, Sébastien +11 morecore +1 more sourceCombining cell-free DNA fragmentomes and total tumour volume improves prognostication and tumour response evaluation in patients with colorectal cancer liver metastases
Background: Treatment decisions in patients with unresectable colorectal liver metastases (CRLM) are largely guided by radiological response to induction systemic therapy.Stoker, Jaap, Verpalen, Inez, van 't Erve, Iris, van den Bergh, Janneke, Kok, Niels F.M., Moos, Shira, Kemna, Ruby, van Waesberghe, Jan Hein, Bond, Marinde J.G., Lumbard, Keith, Huiskens, Joost, van Steijn, Denise, Alipanahi, Bahar, Huitink, Iris, Zeeuw, J. Michiel, Ali, Mahsoem, Giovannetti, Elisa, Dracopoli, Nicholas C., Wesdorp, Nina J., Rinaldi, Lorenzo, Meiqari, Lana, Epi Kanker Team B, Fijneman, Remond J.A., Kazemier, Geert, Punt, Cornelis J.A., Nota, Irena, Leal, Alessandro, Skidmore, Zachary L., Velculescu, Victor E., van den Broek, Daan, Scharpf, Robert B., Meijer, Gerrit A., Swijnenburg, Rutger Jan, Crnovrsanin, Nerma, Cancer +34 morecore Mechanistic Modeling of Joint Circulating Cell-free DNA Concentration—Tumor Size Kinetics under Immune-Checkpoint Inhibitors in Advanced Cancer
International audienceObjectivesIn cancer patients, the plasmatic concentration of global cfDNA — shed by both tumor and wild-type (especially immune) cells — rises and fluctuates with tumor size, number of metastases, and treatment[1].Boutonnet, Audrey, Della-Negra, Lucie, Nguyen Phuong, Linh, Greillier, Laurent, Garcia, Jean-Charles, Benzekry, Sébastien, Fina, Frederic, Tomasini, Pascale, Gaudy-Marqueste, Caroline, Salas, Sébastien, Ginot, Frédéric, Zakrajsek, Romain, Deville, Jean-Laurent +12 morecore +2 more sources